推荐产品
等級
pharmaceutical primary standard
API 家族
cilazapril
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Cilazapril impurity D EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
Leszek Tylicki et al.
Scandinavian journal of urology and nephrology, 42(4), 381-388 (2009-02-21)
Despite the proven effectiveness of combination therapy with an angiotensin I-converting enzyme inhibitor (ACEI) and angiotensin II-receptor blockers (ARBs) for the prevention and treatment of kidney disease, it has not proved possible to inhibit the progress of chronic nephropathies completely.
High-dose angiotensin-converting enzyme inhibitor attenuates oxidative stress in patients with chronic kidney disease.
Marcin Renke et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 24(2), 689-690 (2008-12-05)
IgA nephropathy: a disease in search of a large-scale clinical trial to reliably inform practice.
Giovanni F M Strippoli et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 53(1), 5-8 (2008-12-23)
Mustafa Tuncer et al.
Advances in therapy, 25(2), 99-105 (2008-02-26)
P-wave dispersion (PWD) has been shown to be a non-invasive electrocardiographic predictor for development of atrial fibrillation (AF). Thus, it may be possible to decrease AF risk through improvement in PWD. Our objective was to compare the effects of cilazapril
Yan-Xing Zhang et al.
Internal medicine (Tokyo, Japan), 47(9), 867-875 (2008-05-03)
Reversible posterior encephalopathy syndrome (RPES) is a clinical entity characterized with headache, nausea, vomiting, seizures, consciousness disturbance, and frequently visual disorders associated with neuroradiological findings, predominantly white matter abnormalities of the parieto-occipital lobes. The central nervous system manifestations of systemic
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门